Dr. Lupo Served on the Advisory Board for Newly Approved Rosacea Product

The FDA recently approved Mirvaso (brimonidine, Galderma) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. The once-daily medication works quickly to reduce the redness of rosacea and lasts up to 12 hours. The approval was based on the results of two Phase III studies showing that adults who used Mirvaso demonstrated significantly greater improvement in the facial redness of rosacea than vehicle gel. Galderma says it expects Mirvaso to be available in pharmacies in September 2013. 


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s